OP18: Treatment of perianal fistulas in Crohn’s Disease: Surgical closure after anti-TNF induction treatment versus anti-TNF without surgery (PISA II) - A patient preference RCTECCO'21 VirtualYear: 2021
Authors: Meima - van Praag, E.(1);van Rijn, K.(2);Snijder, A.(3);Wasmann, K.(4);Stoker, J.(2);D'Haens, G.(3);Gecse, K.(3);Gerhards, M.(5);Jansen, J.(6);Pronk, A.(7);van Tyl, S.(8);Zimmerman, D.(9);Bruin, K.(10);Spinelli, A.(11);Danese, S.(12);van der Bilt, J.(13);Mundt, M.(14);Bemelman, W.(1);Buskens, C.(1)
(1)Amsterdam UMC, Surgery, Amsterdam, The Netherlands;(2)Amsterdam UMC, Radiology and Nuclear Medicine, Amsterdam, The Netherlands;(3)Amsterdam UMC, Gastroenterology and Hepatology, Amsterdam, The Netherlands;(4)Amsterdam UMC, Surgery, Amsterda-, The Netherlands;(5)OLVG, Surgery, Amsterdam, The Netherlands;(6)OLVG, Gastroenterology and Hepatology, Amsterdam, The Netherlands;(7)Diakonessenhuis, Surgery, Utrecht, The Netherlands;(8)Diakonessenhuis, Gastroenterology and Hepatology, Utrecht, The Netherlands;(9)Elisabeth-TweeSteden Hospital, Surgery, Tilburg, The Netherlands;(10)Elisabeth-TweeSteden Hospital, Gastroenterology and Hepatology, Tilburg, The Netherlands;(11)Humanitas Research Hospital and Humanitas University, Surgery, Milan, Italy;(12)Humanitas Research Hospital and Humanitas University, Gastroenterology, Milan, Italy;(13)Flevoziekenhuis, Surgery, Almere, The Netherlands;(14)Flevoziekenhuis, Gastroenterology and Hepatology, Almere, The Netherlands
OP19: Disease course and treatment outcomes of early resected Crohn's Disease patients: A Danish nationwide cohort study from 1997 to 2015ECCO'21 VirtualYear: 2021
Authors: Sarikaya, M.(1);Zhao, M.(2);Bendtsen, F.(1,2);Burisch, J.(2)
(1)University of Copenhagen- Copenhagen- Denmark, Faculty of Health Sciences, Copenhagen, Denmark;(2)Hvidovre University Hospital- Kettegaard Alle 30, The Gastro Unit- Medical Division, Hvidovre, Denmark
OP20: Risk and predictors of surgery in a newly diagnosed cohort of IBD patients in the biologic era: Results from the EpidemIBD studyECCO'21 VirtualYear: 2021
Authors: Chaparro, M.(1);Garre, A.(1);Núñez Ortiz , A.(2);Diz-Lois Palomares, M.T.(3);Rodríguez, C.(4);Riestra, S.(5);Vela, M.(6); Benítez, J.M.(7);Fernández Salgado, E.(8);Sánchez Rodríguez, E.(9);Hernández, V.(10);Ferreiro-Iglesias, R.(11);Ponferrada Díaz, Á.(12);Barrio, J.(13); Huguet, J.M.(14);Arias, L.(15);Martín-Arranz, M.D.(16);Calvet, X.(17);Ginard, D.(18);Alonso-Abreu, I.(19);Fernández-Salazar, L.(20);Varela Trastoy, P.(21);Rivero, M.(22);Vera-Mendoza, I.(23);Vega, P.(24);Navarro, P.(25);Sierra, M.(26); Cabriada, J.L.(27);Aguas, M.(28);Vicente, R.(29);Navarro-Llavat, M.(30);Echarri, A.(31);Gomollón, F.(32);Guerra del Río, E.(33);Casanova, M.J.(1);Spicakova, K.(34);Ortiz de Zarate, J.(35);Alonso-Galán, H.(36);Barreiro-de Acosta, M.(11);Gisbert, J.P.(1)
(1)Hospital Universitario de La Princesa- Instituto de Investigación Sanitaria Princesa IIS-IP- Universidad Autónoma de Madrid- and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBERehd, Gastroenterology Unit, Madrid, Spain;(2)Hospital Universitario Virgen del Rocío, Gastroenterology Unit, Sevilla, Spain;(3)Hospital Universitario A Coruña, Gastroenterology Unit, A Coruña, Spain;(4)Complejo Hospitalario de Navarra, Gastroenterology Unit, Pamplona, Spain;(5)Hospital Universitario Central de Asturias and ISPA, Gastroenterology Unit, Oviedo, Spain;(6)Complejo Hospitalario Universitario Ntra. Sra. de Candelaria, Gastroenterology Unit, Santa Cruz de Tenerife, Spain;(7)Hospital Universitario Reina Sofía and IMIBIC, Gastroenterology Unit, Córdoba, Spain;(8)Complexo Hospitalario Universitario de Pontevedra- Instituto de Investigación Sanitaria Galicia Sur, Gastroenterology Unit, Pontevedra, Spain;(9)Hospital Ramón y Cajal, Gastroenterology Unit, Madrid, Spain;(10)Hospital Álvaro Cunqueiro. Estrutura Organizativa de Xestión Integrada de Vigo, Gastroenterology Unit, Vigo, Spain;(11)Complexo Hospitalario Universitario de Santiago, Gastroenterology Unit, Santiago de Compostela, Spain;(12)Hospital Universitario Infanta Leonor, Gastroenterology Unit, Madrid, Spain;(13)Hospital Universitario Rio Hortega, Gastroenterology Unit, Valladolid, Spain;(14)Consorcio Hospital General Universitario de Valencia, Gastroenterology Unit, Valencia, Spain;(15)Hospital Universitario de Burgos, Gastroenterology Unit, Burgos, Spain;(16)Hospital Universitario La Paz- School of Medicine. Universidad Autónoma de Madrid. Hospital La Paz Institute for Health Research- La Paz Hospital, Gastroenterology Unit, Madrid, Spain;(17)Hospital Universitari Parc Taulí- Sabadell. Departament de Medicina- Universitat Autònoma de Barcelona. CIBERehd - Instituto de Salud Carlos III, Gastroenterology Unit, Barcelona, Spain;(18)Hospital Universitari Son Espases, Gastroenterology Unit, Palma de Mallorca, Spain;(19)Hospital Universitario de Canarias H.U.C, Gastroenterology Unit, Santa Cruz de Tenerife, Spain;(20)Hospital Clínico Universitario de Valladolid, Gastroenterology Unit, Valladolid, Spain;(21)Hospital de Cabueñes, Gastroenterology Unit, Gijón, Spain;(22)Hospital Universitario Marqués de Valdecilla and IDIVAL, Gastroenterology Unit, Santander, Spain;(23)Hospital Universitario Puerta de Hierro Majadahonda, Gastroenterology Unit, Madrid, Spain;(24)Complexo Hospitalario Universitario de Ourense, Gastroenterology Unit, Ourense, Spain;(25)Hospital Clínico Universitario de Valencia- Universitat de València, Gastroenterology Unit, Valencia, Spain;(26)Complejo Asistencial Universitario de León, Gastroenterology Unit, León, Spain;(27)Hospital de Galdakao-Usansolo, Gastroenterology Unit, Galdakao, Spain;(28)Hospital Universitari i Politecnic La Fe and CIBERehd, Gastroenterology Unit, Valencia, Spain;(29)Hospital Universitario Miguel Servet, Gastroenterology Unit, Zaragoza, Spain;(30)Hospital de Sant Joan Despí Moisès Broggi, Gastroenterology Unit, Barcelona, Spain;(31)Complejo Hospitalario Universitario de Ferrol, Gastroenterology Unit, A Coruña, Spain;(32)Hospital Clínico Universitario “Lozano Blesa”- IIS Aragón and CIBERehd, Gastroenterology Unit, Zaragoza, Spain;(33)Hospital Universitario de Gran Canaria Dr. Negrín, Gastroenterology Unit, Las Palmas, Spain;(34)Hospital Universitario de Araba sede Txagorritxu y sede Santiago, Gastroenterology Unit, Álava, Spain;(35)Hospital Universitario de Basurto, Gastroenterology Unit, Bilbao, Spain;(36)Hospital Universitario Donostia-Donostia Unibertsitate Ospitalea- Guipuzkoa and Organizacion Sanitaria Integrada Tolosaldea- Clínica Santa María de la Asunción, Gastroenterology Unit, Guipúzcoa, Spain On behalf of EpidemIBD Study Group
OP21: Predictive value of Milan Ultrasound Criteria in Ulcerative Colitis: A prospective observational cohort studyECCO'21 VirtualYear: 2021
Authors: Allocca, M.(1);Dell’Avalle, C.(2);Furfaro, F.(2);Craviotto, V.(2);Zilli, A.(2);D'Amico, F.(2);Peyrin-Biroulet, L.(3);Fiorino, G.(1);Danese, S.(1)
(1)Humanitas University- Pieve Emanuele, Department of Biomedical Sciences, Milan, Italy;(2)Humanitas Clinical and Research Center – IRCCS Rozzano, IBD Unit, Milan, Italy;(3)University Hospital of Nancy- Université de Lorraine, Department of Gastroenterology, Nancy, Italy
OP22: Factors independently associated with fatigue in IBD: Results from the baseline dataset of the PREdiCCt studyECCO'21 VirtualYear: 2021
Authors: Derikx, L.(1,2);Siakavellas, S.(2);Derr, L.(2);Williams, L.(2);Nikolas, P.(2);Jenkinson, P.(2);Lucaciu, L.(2);Constantine-Cooke, N.(3);Covil, K.(2);Murdoch, L.(2);Jones, G.R.(2,4);Lees, C.(2,5)
(1)Radboud University Nijmegen Medical Centre, Inflammatory Bowel Disease Centre- Department of Gastroenterology and Hepatology- Route 455, Nijmegen, The Netherlands;(2)Western General Hospital, The Edinburgh IBD Unit, Edinburgh, United Kingdom;(3)University of Edinburgh- Western General Hospital, MRC Human Genetics Unit- Institute of Genetics and Molecular Medicine, Edinburgh, United Kingdom;(4)University of Edinburgh, Centre for Inflammation Research- The Queen's Medical Research Institute, Edinburgh, United Kingdom;(5)University of Edinburgh- Western General Hospital, Centre for Genomics and Experimental Medicine- Institute of Genetics and Molecular Medicine, Edinburgh, United Kingdom PREdiCCt Study Writing Group
OP23: Efficacy and safety of upadacitinib as induction therapy in patients with Moderately to Severely Active Ulcerative Colitis: Results from phase 3 U-ACCOMPLISH studyECCO'21 VirtualYear: 2021
Authors: Vermeire, S.(1);Danese, S.(2);Zhou, W.(3);Pangan, A.(3);Greenbloom, S.(4);D'Haens, G.(5);Panes, J.(6);Juillerat, P.(7);Lindsay, J.O.(8);Loftus Jr, E.V.(9);Sandborn, W.J.(10);Reinisch, W.(11);Sanchez Gonzalez, Y.(3);Huang, B.(3);Xie, W.(3);Liu, J.(3);Weinreich, M.A.(3);Panaccione, R.(12)
(1)KU Leuven, Gastroenterology, Leuven, Belgium;(2)Instituto Clinico Humanitas, Gastroenterology, Milan, Italy;(3)AbbVie Inc., Research & Development, North Chicago- Illinois, United States;(4)Toronto Digestive Disease Associates, Clinical Research, Ontario, Canada;(5)Amsterdam UMC campus AMC, Gastroenterology, Amsterdam, Netherlands Antilles;(6)Hospital Clínic Barcelona- IDIBAPS- CIBERehd, Inflammatory Bowel Diseases Unit, Barcelona, Spain;(7)Bern University Hospital- Clinic for Visceral Surgery and Medicine, Gastroenterology, Bern, Switzerland;(8)Barts and the London School of Medicine and Dentistry- Queen Mary University of London, Centre for Immunobiology, London, United Kingdom;(9)Mayo Clinic, Division of Gastroenterology and Hepatology, Rochester- Minnesota, United States;(10)University of California San Diego, Division of Gastroenterology, La Jolla- California, United States;(11)Medical University of Vienna, Gastroenterology, Vienna, Austria;(12)University of Calgary, Division of Gastroenterology, Calgary- Alberta, Canada
OP24: Efficacy and safety of upadacitinib induction therapy in patients with Moderately to Severely Active Ulcerative Colitis: Results from the phase 3 U-ACHIEVE studyECCO'21 VirtualYear: 2021
Authors: Danese, S.(1);Vermeire , S.(2);Zhou, W.(3);Pangan, A.(4);Siffledeen, J.(5);Hébuterne, X.(6);Nakase, H.(7);Higgins, P.(8);Chen, M.H.(9);Sanchez-Gonzalez, Y.(3);Huang, B.(3);Xie, W.(4);Liu, J.(4);Weinreich, M.(4);Pannaccione, R.(10)
(1)IRCCS Humanitas Research Hospital, Department of Gastroenterology, Rozzano, Italy;(2)2University Hospital Leuven, Department of Gastroenterology & Hepatology, Leuven, Belgium;(3)AbbVie Inc, na, North Chicago, United States;(4)AbbVie Inc., na, North Chicago, United States;(5)University of Alberta, na, Edmonton, Canada;(6)Université Côte d’Azur, na, Nice, France;(7)Sapporo Medical University School of Medicine, Department of Gastroenterology and Hepatology, Sapporo, Japan;(8)University of Michigan, Department of Medicine- Division of Gastroenterology, Ann Arbor, United States;(9)The First Affiliated Hospital of Sun Yat-sen University, Division of Gastroenterology, Guangzhou, China;(10)University of Calgary, Division of Gastroenterology, Calgary, Canada
OP25: Efficacy of filgotinib in patients with Ulcerative Colitis by line of therapy in the phase 2b/3 SELECTION trialECCO'21 VirtualYear: 2021
Authors: Peyrin-Biroulet, L.(1);Dotan, I.(2,3);Hibi, T.(4);Taliadouros, V.(5);Oortwijn, A.(5);Zhao, S.(6);Zhang, J.(6);Hsieh, J.(6);Feagan, B.(7,8)
(1)Nancy University Hospital, Inflammatory Bowel Disease Unit, Nancy, France;(2)Rabin Medical Center Beilinson Hospital, Division of Gastroenterology, Petah Tikva, Israel;(3)Tel Aviv University, Sackler Faculty of Medicine, Tel Aviv, Israel;(4)Kitasato Institute Hospital Kitasato University, Center for Advanced IBD Research and Treatment, Tokyo, Japan;(5)Galapagos, Nv, Leiden, The Netherlands;(6)Gilead Sciences, Inc., Foster City CA, United States;(7)Alimentiv Inc., London, Ontario, Canada;(8)Western University, London, Ontario, Canada
OP26: Risankizumab induces early clinical remission and response in patients with Moderate-to-Severe Crohn’s Disease: Results from the phase 3 ADVANCE and MOTIVATE studiesECCO'21 VirtualYear: 2021
Authors: Schreiber , S.W.(1);Ferrante , M.(2);Panaccione , R.(3);Colombel , J.F.(4);Hisamatsu , T.(5);Lim , A.(6);Lindsay , J.O.(7);Rubin , D.T.(8);Sandborn , W.J.(9);Neimark , E.(10);Song , A.P.(10);Liao , X.(10);Feng , T.(10);Berg , S.(10);Wallace , K.(10);D’Haens , G.R.(11)
(1)University Hospital Schleswig-Holstein, Kiel, Germany;(2)University Hospitals Leuven, University Hospitals Leuven, Leuven, Belgium;(3)University of Calgary, Calgary, Canada;(4)Icahn School of Medicine at Mount Sinai, New York, United States;(5)Kyorin University School of Medicine, Mitaka, Japan;(6)John Flynn Private Hospital, Tugun, Australia;(7)Barts and the London School of Medicine and Queen Mary University of London, London, United Kingdom;(8)The University of Chicago Medicine Inflammatory Bowel Disease Center, Chicago, United States;(9)University of California San Diego, La Jolla, United States;(10)AbbVie Inc, North Chicago, United States;(11)Amsterdam University Medical Center, Amsterdam, The Netherlands
OP28: The effect of guselkumab induction therapy on early clinical outcome measures in patients with Moderately to Severely Active Crohn’s Disease: Results from the phase 2 GALAXI 1 studyECCO'21 VirtualYear: 2021
Authors: Danese, S.(1);Sandborn, W.J.(2);Feagan, B.G.(3);Weisel, K.(4);Gonzalez, S.(4);Frustaci, M.E.(4);Yang, Z.(4);Johanns, J.(4);Germinaro, M.(4);Afzali, A.(5);Andrews, J.M.(6);D’Haens, G.(7);Hisamatsu, T.(8);Panaccione, R.(9);Reinisch, W.(10);Rubin, D.T.(11);Sands, B.E.(12);Panes, J.(13)
(1)Humanitas Research Hospital, Inflammatory Bowel Diseases Center, Milan, Italy;(2)University of California San Diego, Health Sciences- Gastroenterology, La Jolla- California, United States;(3)Robarts Clinical Trials-Western University, Gastroenterology, London- Ontario, Canada;(4)Janssen Research & Development- LLC, Immunology, Spring House- Pennsylvania, United States;(5)Ohio State University Wexner Medical Center, Gastroenterology, Columbus Ohio, United States;(6)Royal Adelaide Hospital & University of Adelaide, Dept of Gastroenterology and Hepatology, Adelaide- South Australia, Australia;(7)Amsterdam UMC, Gastroenterology, Amsterdam, The Netherlands;(8)Kyorin University, Gastroenterology and Hepatology, Tokyo, Japan;(9)University of Calgary, Gastroenterology & Hepatology, Calgary- Alberta, Canada;(10)Medical University of Vienna, Division of Gastroenterology and Hepatology, Vienna, Austria;(11)University of Chicago Medicine Inflammatory Bowel Disease Center, Gastroenterology, Chicago- Illinois, United States;(12)Icahn School of Medicine at Mount Sinai, Gastroenterology, New York- New York, United States;(13)Hospital Clínic de Barcelona- IDIBAPS- CIBERehd, Gastroenterology, Barcelona, Spain GALAXI 1 Investigators
OP29: Long-term dietary patterns are associated with pro-inflammatory and anti-inflammatory features of the gut microbiomeECCO'21 VirtualYear: 2021
Authors: Bolte, L.(1,2);Vich Vila, A.(1,2);Imhann, F.(1,2);Collij, V.(1,2);Peters, V.(1);Fu, J.(2,3);Kurilshikov, A.(2);Campmans-Kuijpers, M.(1);Dijkstra, G.(1);Wijmenga, C.(2);Zhernakova, A.(2);Weersma, R.(1)
(1)University Groningen and University Medical Center Groningen, Dept. of Gastroenterology & Hepatology, Groningen, The Netherlands;(2)University Groningen and University Medical Center Groningen, Dept. of Genetics, Groningen, The Netherlands;(3)University Groningen and University Medical Center Groningen, Dept. of Paediatrics, Groningen, The Netherlands
OP30: Lyophilised orally administered faecal microbiota transplantation for Active Ulcerative Colitis (LOTUS study)ECCO'21 VirtualYear: 2021
Authors: Haifer, C.(1);Saikal, A.(2);Paramsothy, S.(1);Borody, T.J.(3);Ghaly, S.(2);Kaakoush, N.O.(4);Leong, R.(1)
(1)The University of Sydney, Concord Clinical School, Sydney, Australia;(2)St Vincent's Hospital Sydney, Department of Gastroenterology and Hepatology, Sydney, Australia;(3)Centre for Digestive Diseases, Centre for Digestive Diseases, Sydney, Australia;(4)The University of New South Wales, Faculty of Medicine, Sydney, Australia
OP31: RESTORE: Interim analysis of a Phase 2 study of QBECO SSI for the induction and maintenance of clinical and endoscopic remission in subjects with Moderate to Severe Crohn’s DiseaseECCO'21 VirtualYear: 2021
Authors: Bressler, B.(1);Marshall, J.K.(2);Atkinson, K.(3);Sutcliffe, S.(4);Pankovich, J.(4);Jones, M.(4);Kalyan, S.(4);Gunn, H.(4)
(1)Gastrointestinal Research Institute, Vancouver, British Columbia, Canada;(2)McMaster University, Hamilton, Ontario, Canada;(3)Royal Columbian Hospital, New Westminster, British Columbia, Canada;(4)Qu Biologics Inc, Burnaby, British Columbia, Canada
OP32: Stool microbiome communities predict remission in treatment-naïve Pediatric Crohn’s Disease patientsECCO'21 VirtualYear: 2021
Authors: Verburgt, C.(1,2);Dunn, K.(3);Bielawski, J.(3,4);Otley, A.(5);Heyman, M.(6);Sunseri, W.(7);Shouval, D.(8);Levine, A.(9);de Meij, T.(1);Hyams, J.(10);Denson, L.(11);Kugathasan, S.(12);Benninga, M.(1);de Jonge, W.(2,13);Van Limbergen, J.(1,2,5)
(1)Amsterdam University Medical Centers- Emma Children’s Hospital, Department of Paediatric Gastroenterology and Nutrition, Amsterdam, The Netherlands;(2)Tytgat Institute for Liver and Intestinal Research, Amsterdam Gastroenterology Endocrinology and Metabolism, Amsterdam, The Netherlands;(3)Dalhousie University, Department of Biology, Halifax, Canada;(4)Dalhousie University, Department of Mathematics & Statistics, Halifax, Canada;(5)Dalhousie University, Department of Paediatrics, Halifax, Canada;(6)University of California, UCSF Benioff Children’s Hospital and Department of Paediatrics, San Francisco, United States;(7)UPMC Children’s Hospital of Pittsburgh, Department of Pediatrics, Pittsburgh, United States;(8)Edmond and Lily Safra Children’s Hospital- Sheba Medical Center- Ramat Gan- Israel- Sackler Faculty of Medicine- Tel Aviv University, Pediatric Gastroenterology unit, Tel Aviv, Israel;(9)Wolfson Medical Center- Holon- Israel- Sackler School of Medicine- Tel Aviv University, Pediatric Gastroenterology and Nutrition Unit, Tel Aviv, Israel;(10)Connecticut Children’s Medical Center, Division of Digestive Diseases- Hepatology and Nutrition, Hartford, United States;(11)Cincinnati Children’s Hospital Medical Center and the University of Cincinnati College of Medicine, Department of pediatrics, Cincinatti, United States;(12)Emory University, Department of Pediatrics, Atlanta, United States;(13)University of Bonn, Department of Surgery, Bonn, Germany
OP33: Oral ritlecitinib and brepocitinib in patients with Moderate to Severe Active Ulcerative Colitis: Data from the VIBRATO umbrella studyECCO'21 VirtualYear: 2021
Authors: Sandborn, W.(1);Danese, S.(2);Leszczyszyn, J.(3);Romatowski, J.(4);Altintas, E.(5);Peeva, E.(6);Vincent, M.(6);Reddy, P.(7);Banfield, C.(7);Banerjee, A.(7);Gale, J.(6);Hung, K.(6)
(1)University of California San Diego, Gastroenterology, La Jolla, United States;(2)Humanitas Research Hospital, Gastroenterology, Milan, Italy;(3)Melita Medical, Gastroenterology, Wroclaw, Poland;(4)Provincial Complex Hospital, Gastroenterology, Bialystok, Poland;(5)Mersin University, Gastroenterology, Mersin, Turkey;(6)Pfizer Inc., Inflammation and Immunology, Cambridge, United States;(7)Pfizer Inc., Early Clinical Development, Cambridge, United States
OP34: AJM300, an Oral Antagonist of α4-Integrin, as induction therapy for patients with Moderately Active Ulcerative Colitis: A Phase 3, randomized, double-blind, placebo-controlled induction studyECCO'21 VirtualYear: 2021
Authors: Watanabe, M.(1);Matsuoka, K.(2); Ohmori, T.(3);Nakajima, K.(4);Ishida, T.(5);Ishiguro , Y.(6);Kanke, K.(7);Kobayashi, K.(8);Hirai, F.(9);Watanabe, K.(10);Hibi, T.(11)
(1)Tokyo Medical and Dental University, Advanced Research Institute, Tokyo, Japan;(2)Toho University Sakura Medical Center, Department of Gastroenterology and Hematology, Chiba, Japan;(3)Ohmori Toshihide gastro-intestinal Clinic, Gastroenterology, Saitama, Japan;(4)Matsushima Clinic Yokohama Japan, Department of gastrointestinal division, Kanagawa, Japan;(5)Ishida Clinic of IBD and Gastroenterology, IBD and Gastroenterology, Oita, Japan;(6)National Hospital Organization Hirosaki National Hospital, Department of Gastroenterology and Hematology, Aomori, Japan;(7)Kanke Gastrointestinal Clinic, Gastrointestinal division, Tochigi, Japan;(8)Kitasato University School of Medicine, Research and Development Center for New Medical Frontiers, Kanagawa, Japan;(9)Fukuoka University Hospital, Department of Gastroenterology and Medicine, Fukuoka, Japan;(10)Hyogo College Of Medicine College Hospital, Department of Intestinal Inflammation Research, Hyogo, Japan;(11)Kitasato University Kitasato Institute Hospital, Center for Advanced IBD Research and Treatment, Tokyo, Japan
OP35: Effect of maintenance ustekinumab on corticosteroid-free endoscopic and clinical outcomes in patients with Crohn's Disease - Week 48 analysis of the STARDUST trialECCO'21 VirtualYear: 2021
Authors: Danese, S.(1);Vermeire, S.(2);D’Haens, G.(3);Panés, J.(4);Dignass, A.(5);Magro, F.(6,7);Nazar, M.(8);Le Bars, M.(9);Lahaye, M.(10);Ni, L.(11);Bravatà, I.(12);Gaya, D.R.(13);Peyrin-Biroulet, L.(14)
(1)Humanitas University, IBD Center, Milan, Italy;(2)University Hospitals Leuven, Department of Gastroenterology, Leuven, Belgium;(3)University of Amsterdam, Academic Medical Center, Amsterdam, The Netherlands;(4)Hospital Clinic of Barcelona- IDIBAPS- CIBERehd, Department of Gastroenterology, Barcelona, Spain;(5)Agaplesion Markus Hospital, Department of Medicine I, Frankfurt/Main, Germany;(6)Institute for Molecular and Cell Biology- Faculty of Medicine University of Porto, Department of Pharmacology & Therapeutics, Porto, Portugal;(7)Hospital de São João, Department of Gastroenterology, Porto, Portugal;(8)Janssen-Cilag Polska Sp. z .o.o., Medical Affairs, Warsaw, Poland;(9)Janssen-Cilag, Medical Affairs, Issy-les-Moulineaux, France;(10)Janssen-Cilag BV, Medical Affairs, Breda, The Netherlands;(11)Janssen Cilag Russia, Medical Affairs, Moscow, Russian Federation;(12)Janssen-Cilag, Medical Affairs, Milan, Italy;(13)Glasgow Royal Infirmary, Department of Gastroenterology, Glasgow, United Kingdom;(14)University Hospital of Nancy- University of Lorraine, INSERM Unité 954 and Department of Hepato-Gastroenterology, Houdemont, France
OP36: Risankizumab therapy induces improvements in endoscopic endpoints in patients with Moderate-to-Severe Crohn’s Disease: Results from the phase 3 ADVANCE and MOTIVATE studiesECCO'21 VirtualYear: 2021
Authors: Bossuyt, P.(1);Ferrante, M.(2);Baert, F.(3);Danese, S.(4);Feagan, B.G.(5);Loftus Jr, E.V.(6);Panés, J.(7);Peyrin-Biroulet, L.(8);Ran, Z.(9);Armuzzi, A.(10);D’Haens, G.R.(11);SONG, A.(12);Neimark, E.(12);Liao, X.(12);Zhou, Q.(12);Berg, S.(12);Wallace, K.(12);Panaccione, R.(13)
(1)Imelda General Hospital, Bonheiden, Belgium;(2)University Hospitals Leuven, Leuven, Belgium;(3)AZ Delta, Roeselare-Menen, Belgium;(4)Istituto Clinico Humanitas, Milan, Italy;(5)Western University, London, Canada;(6)Mayo Clinic, Rochester, United States;(7)Hospital Clinic Barcelona, Barcelona, Spain;(8)University Hospital of Nancy and Lorraine University, Vandoeuvre, France;(9)Shanghai Jiao Tong University, Shanghai, China;(10)Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy;(11)Amsterdam University Medical Centers, Amsterdam, The Netherlands;(12)AbbVie Inc, North Chicago, United States;(13)University of Calgary, Calgary, Canada
OP37: Rapidity of symptom improvements during filgotinib induction therapy in patients with Ulcerative Colitis: Post hoc analysis of the phase 2b/3 SELECTION studyECCO'21 VirtualYear: 2021
Authors: Danese, S.(1);Hibi, T.(2);Ritter, T.E.(3);Dinoso, J.B.(4);Hsieh, J.(4);Yun, C.(4);Zhang, J.(4);Zhao, S.(4);Loftus Jr, E.V.(5);Rogler, G.(6)
(1)Humanitas Clinical and Research Center- IRCCS and Humanitas University, Department of Gastroenterology, Milan, Italy;(2)Kitasato Institute Hospital- Kitasato University, Center for Advanced IBD Research and Treatment, Tokyo, Japan;(3)GI Alliance, Department of Research and Education, Southlake- TX, United States;(4)Gilead Sciences, Inc., Foster City, United States;(5)Mayo Clinic, Department of Internal Medicine- Division of Gastroenterology and Hepatology, Rochester- MN, United States;(6)University Hospital of Zurich- University of Zurich, Clinic for Gastroenterology and Hepatology, Zurich, Switzerland